论文部分内容阅读
目的 通过总结我院 17年来初治急性白血病诱导治疗结果 ,了解目前诱导治疗现状。方法 采用回顾性分析方法 ,查阅 17年来我院所有住院的急性初治白血病病例共 34 7例 ,对其诱导化疗方案、治疗效果及毒性反应等进行统计分析。结果 采用 DA及 HOAP方案治疗非 M3 的 AML患者 ,CR率分别为 5 7.1%及 5 9.5 % ,两者并无显著性差异。而应用 HOAP治疗 AML - M3 患者 ,CR率仅为 14.2 % ,应用 ATRA诱导缓解后加 DA方案治疗 ,CR率达到 77.3%。 VEAGP及 VDL P治疗 AL L的 CR率分别为 62 .5 %及 5 9.1%。初治死亡患者中 ,颅内出血占 40 % (30 / 75 ) ,各种感染占 37.3% (2 8/ 75 )。结论 除 M3 患者外 ,不同诱导化疗方案治疗急性白血病的 CR率并无显著性差异。颅内出血、感染因素为初治诱导化疗常见死亡原因 ,且并未逐年减少。
Objective To summarize the results of induction therapy of newly diagnosed acute leukemia in our hospital over the past 17 years to understand the current status of induction therapy. Methods A retrospective analysis of access to all 17 hospitalized cases of acute leukemia in our hospital were a total of 347 cases of its induction of chemotherapy regimens, treatment and toxicity were statistically analyzed. Results The DA and HOAP regimens for the treatment of non-M3 AML patients had CR rates of 51.1% and 5 9.5%, respectively, with no significant difference between the two. The application of HOAP in the treatment of AML - M3 patients, CR rate was only 14.2%, the application of ATRA induced remission plus DA regimen, CR rate reached 77.3%. The CR rates of VEAGP and VDL P for AL L were 62.5% and 51.9% respectively. Among the newly diagnosed patients, intracranial hemorrhage accounted for 40% (30/75), and various infections accounted for 37.3% (28/75). Conclusion In addition to M3 patients, different induction chemotherapy regimen in the treatment of acute leukemia CR rate was not significantly different. Intracranial hemorrhage, the infection factor is the common cause of death in the initial induction chemotherapy, and has not decreased year by year.